COMPANY

Qlaris Bio

Profile checked Oct 10, 2026

Keywords: Normal Tension Glaucoma Glaucoma Ocular Hypertension Open-angle Glaucoma Non-proliferative Diabetic Retinopathy OAG - Open-Angle Glaucoma OHT - Ocular Hypertension Bilateral Low-Tension Glaucoma Unspecified Eye Low-Tension Glaucoma Primary Open Angle Glaucoma Primary Open Angle Glaucoma of Both Eyes Unspecified Eye Primary Open-Angle Glaucoma Sturge-Weber Syndrome Glaucoma Congenital QLS-111 QLS-101 QLS-111-FDC

9Trials (company is sponsor)

Funding and NIH signals

SEC Form D raise Raised $3.95M in debt securities (Form D filed Jun 17, 2026); +1 other Form D filing in the last 12 months. SEC Form D 0001786717-26-000002 (Jun 17, 2026)
Evidence (2 events)
- Jun 17, 2026 · SEC Form D 0001786717-26-000002
  Name of Issuer: Qlaris Bio, Inc.; CIK: 1786717; Address: Dedham, MA; Submission type: D; Filing date: 2026-06-17; Industry Group: Biotechnology; Date of First Sale: 2026-06-12; Types of Securities Offered: Debt, Option/warrant, Other (Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 3946659; Total Amount Sold: 3946659; Federal exemptions: 06b
- Nov 17, 2025 · SEC Form D 0001786717-25-000002
  Name of Issuer: Qlaris Bio, Inc.; CIK: 1786717; Address: Dedham, MA; Submission type: D; Filing date: 2025-11-17; Industry Group: Biotechnology; Date of First Sale: 2025-11-13; Types of Securities Offered: Debt, Option/warrant, Other (Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 5641600; Total Amount Sold: 5641600; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Mar 18, 2026 Trial start Phase 2/Phase 3: Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension source ↗
Feb 20, 2026 Trial start Phase 2: Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation source ↗
Aug 13, 2025 Trial start Phase 2: Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG) source ↗
Apr 21, 2024 Trial start Phase 2: Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients source ↗
Mar 5, 2024 Trial start 2: Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients source ↗
Nov 23, 2022 Trial start Phase 2: Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP) source ↗
Oct 19, 2021 Trial start Phase 2: A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101 source ↗
Sep 15, 2021 Trial start Phase 2: A Study to Evaluate Safety and Tolerability of QLS-101 in NTG source ↗
Mar 31, 2021 Trial start Phase 2: Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension). source ↗

Upcoming milestones

2026-10 (ESTIMATED) · Phase 2 · Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation · NCT07354477

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 9

Record	Title	Phase	Status	Start	Primary completion
NCT07354477	Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation	Phase 2	Active, not recruiting	Feb 20, 2026	2026-10 (estimated)
NCT07354516	Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension	Phase 2/Phase 3	Completed	Mar 18, 2026	Jul 22, 2026 (actual)
NCT06030193	Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)	Phase 2	Completed	Aug 13, 2025	Feb 23, 2026 (actual)
NCT06016972	Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients	2	Completed	Mar 5, 2024	Aug 20, 2024 (actual)
NCT06249152	Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients	Phase 2	Completed	Apr 21, 2024	Dec 20, 2024 (actual)
NCT05495269	Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)	Phase 2	Completed	Nov 23, 2022	Jan 25, 2023 (actual)
NCT04947124	A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101	Phase 2	Completed	Oct 19, 2021	Jun 6, 2022 (actual)
NCT04857827	A Study to Evaluate Safety and Tolerability of QLS-101 in NTG	Phase 2	Completed	Sep 15, 2021	Aug 26, 2022 (actual)
NCT04830397	Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).	Phase 2	Completed	Mar 31, 2021	Feb 17, 2022 (actual)